dironyl (terguride)

pronounced antifertility agent in rats; lactation suppressor in other species; serotonin antagonist; RN given refers to parent cpd; structure

Also Known As:

terguride; N-(D-6-methyl-8-isoergolin-1-yl)-N',N'-diethylurea; VUFB 6638; dironyl maleate (1:1); transdihydrolisuride; urea, N,N-diethyl-N'-((8 alpha)-6-methylergolin-8-yl)-, (Z)-2-butenedioate (1:1)

Networked: 72 relevant articles (11 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Ergot Alkaloids: 208
    - Ergolines: 109
      - Lisuride: 246
        dironyl: 72
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - Ergolines: 109
      - Lisuride: 246
        dironyl: 72

Experts

1.	Golda, V: 3 articles (01/2004 - 01/2001)
2.	Schermuly, Ralph Theo: 2 articles (01/2015 - 11/2010)
3.	Seeger, Werner: 2 articles (01/2015 - 11/2010)
4.	Reiter, Rudolf: 2 articles (11/2010 - 01/2010)
5.	Gustafsson, Björn I: 2 articles (11/2008 - 10/2007)
6.	Waldum, Helge L: 2 articles (11/2008 - 10/2007)
7.	Macho, L: 2 articles (06/2002 - 01/2001)
8.	Pinterova, L: 2 articles (06/2002 - 01/2001)
9.	Kawaguchi, Tomohiro: 1 article (07/2022)
10.	Ogawa, Yoshikazu: 1 article (07/2022)

Related Diseases

1.	Dyskinesias (Dyskinesia) 09/01/1993 - "Terguride for dyskinesias." 08/01/1990 - "Terguride, a partial DA-agonist with both dopaminergic and antidopaminergic properties, was tested in 11 PD patients in the "decompensated" phase of the disease, characterized by the presence of dyskinesias and motor fluctuations. " 04/01/1995 - "Terguride also improved the parkinsonism but did not induce the hyperactivity and dyskinesias. " 08/01/1990 - "Combined treatment of these patients with 1 mg/day of terguride and stabilized doses of levodopa reduced the severity and frequency of dyskinesias and motor fluctuations along with a slight but significant improvement of parkinsonian clinical picture. " 04/01/1995 - "On the other hand, combination treatment of terguride with SKF 82958 also augmented the antiparkinsonian effects but did not induce any hyperactivity and dyskinesias. "
2.	Parkinson Disease (Parkinson's Disease) 05/01/1995 - "Terguride in stable Parkinson's disease." 03/03/1992 - "It is concluded that terguride has anti-akinetic efficacy in this primate model of Parkinson's disease. " 10/01/1991 - "Antagonist effect of terguride in Parkinson's disease." 08/01/1990 - "Terguride in the treatment of Parkinson disease: preliminary experience." 01/01/1987 - "Evaluation of terguride in patients with Parkinson's disease."
3.	Pulmonary Hypertension 12/01/2021 - ""Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats." R. " 05/01/2011 - "Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats." 05/01/2011 - "Therapeutic 5-HT signalling inhibition was 1) demonstrated in isolated, ventilated and perfused rat lungs and 2) by chronic terguride treatment of rats with monocrotaline (MCT)-induced pulmonary hypertension in a preventive or curative approach. "
4.	Fibrosis (Cirrhosis) 11/01/2010 - "Blockade of 5-HTR(2A/B) signalling by terguride reversed lung fibrosis and is thus a promising therapeutic approach for IPF." 01/01/2015 - "Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. " 12/01/2018 - "Terguride and SB204741 reduce pro-fibrotic potential of HADF cells and suppress TGF-β1-mediated non-canonical pathways, ERK1/2 and STAT3 which have been implicated in the regulation of pro-fibrotic genes and in the development of fibrosis. " 11/01/2010 - "To assess the effects of 5HTR(2A/B) inhibition on fibrogenesis in vivo, mice were subjected to bleomycin-induced lung fibrosis and treated with the 5-HTR(2A/B) antagonist terguride (or vehicle) in a therapeutic approach (days 14-28 after bleomycin). " 11/01/2008 - "In the current study, the carbon tetrachloride (CCL(4)) hepatic fibrosis rat model was used in combination with daily administration of terguride to evaluate potential preventive effects of a 5-HT(2) receptor antagonist upon liver fibrosis. "
5.	Pain (Aches) 01/01/2010 - "FIQ scores improved significantly (per-protocol analysis), and pain intensity, the TPS score, and the HDS score showed a trend toward improvement in the terguride group as compared with the placebo group. " 01/01/2010 - "Terguride treatment did not improve pain, the FIQ score, the TPS, or the HDS score in the total study population. " 01/01/2010 - "No significant differences in the change in pain intensity, FIQ score, TPS, or HDS score between baseline and 12 weeks were observed in the terguride group as compared with the placebo group. "

Related Drugs and Biologics

1.	Monocrotaline
2.	Levodopa (L Dopa)
3.	Lisuride
4.	Bromocriptine (Parlodel)
5.	Prolactin
6.	Insulin (Novolin)
7.	N- (1- methyl- 5- indolyl)- N'- (3- methyl- 5- isothiazolyl)urea
8.	Urea (Carbamide)
9.	Ergolines
10.	Antiparkinson Agents (Antiparkinsonian Agents)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Drug Therapy (Chemotherapy)